Xeomin is making smooth moves. The anti-wrinkle injectable, which debuted in 2011 for the treatment of moderate to severe wrinkles between the frown lines (glabellar lines), received FDA approval for ...

Please provide your email address to receive an email when new articles are posted on . 92%, 62% and 60% of subjects were satisfied with their outcomes at months 1, 6 and 12 post-treatment, ...

Please provide your email address to receive an email when new articles are posted on . 43.9% of patients experienced a treatment-emergent adverse event. Only 18.2% were treatment related. Efficacy ...

(Reuters) - Medical aesthetics company Revance Therapeutics Inc said on Tuesday that its long-acting injectable drug was successful in reducing moderate-to-severe frown lines in a late-stage study.

From laugh lines and stretch marks to acne scars and sunspots, our skin tells the story of our lives. But as time ticks on, many of us search for ways to rejuvenate, refresh and maybe hit the “delete” ...

Lydia August, 28, told Newsweek, "I have not shown any improvement," since the treatment was done 12 days ago.